Literature DB >> 20447577

Expression of microRNA-208 is associated with adverse clinical outcomes in human dilated cardiomyopathy.

Mamoru Satoh1, Yoshitaka Minami, Yuji Takahashi, Tsuyoshi Tabuchi, Motoyuki Nakamura.   

Abstract

BACKGROUND: Recently, microRNA-208 (miR-208) encoded by the alpha-myosin heavy chain (MHC) gene, has been shown to be involved in pathological cardiac growth, fibrosis, and up-regulation of beta-MHC expression. A recent study has also reported 2 additional myosin-expressed miRNAs (miR-208b and miR-499). The aim of this study was to determine whether miR-208, miR-208b, and miR-499 are expressed with MHC mRNA in human dilated cardiomyopathy (DCM), and whether these levels are related to left ventricular (LV) function and to clinical outcomes. METHODS AND
RESULTS: Endomyocardial biopsy tissues were obtained from 82 patients with DCM and 21 subjects without LV dysfunction as controls. Levels of miR-208, miR-208b, and miR-499 were higher in DCM patients than in controls. Levels of alpha-MHC mRNA were lower in patients with DCM than in controls, whereas beta-MHC mRNA levels were higher in patients with DCM compared with controls. Levels of miR-208 were correlated with beta-MHC mRNA levels and myocardial collagen volume, whereas levels of miR-208b and miR-499 showed no correlation. After a mean follow-up of 517 days, an increase in miR-208 levels was shown to be a strong predictor of clinical outcomes (RR 3.4, 95% CI 1.1-11.2).
CONCLUSIONS: This study suggests that myocardial expression of miR-208 is associated with MHC mRNA expression and with poor clinical outcomes in patients with DCM. We conclude that miR-208 may therefore be involved in the progression of human DCM.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20447577     DOI: 10.1016/j.cardfail.2010.01.002

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  48 in total

Review 1.  Diagnostic and prognostic value of circulating microRNAs in heart failure with preserved and reduced ejection fraction.

Authors:  Christian Schulte; Dirk Westermann; Stefan Blankenberg; Tanja Zeller
Journal:  World J Cardiol       Date:  2015-12-26

Review 2.  MicroRNAs: redefining mechanisms in cardiac disease.

Authors:  Gerald W Dorn
Journal:  J Cardiovasc Pharmacol       Date:  2010-12       Impact factor: 3.105

Review 3.  MicroRNA208 family in cardiovascular diseases: therapeutic implication and potential biomarker.

Authors:  Ying Huang; Jun Li
Journal:  J Physiol Biochem       Date:  2015-04-04       Impact factor: 4.158

4.  Myocardial microRNAs associated with reverse remodeling in human heart failure.

Authors:  Carmen C Sucharov; David P Kao; J David Port; Anis Karimpour-Fard; Robert A Quaife; Wayne Minobe; Karin Nunley; Brian D Lowes; Edward M Gilbert; Michael R Bristow
Journal:  JCI Insight       Date:  2017-01-26

5.  Circulating MicroRNAs: a Potential Biomarker for Cardiac Damage, Inflammatory Response, and Left Ventricular Function Recovery in Pediatric Viral Myocarditis.

Authors:  Lior Goldberg; Tal Tirosh-Wagner; Amir Vardi; Haya Abbas; Nir Pillar; Noam Shomron; Yael Nevo-Caspi; Gideon Paret
Journal:  J Cardiovasc Transl Res       Date:  2018-06-18       Impact factor: 4.132

6.  Perinatal inflammation induces sex-related differences in cardiovascular morbidities in mice.

Authors:  Markus Velten; Kathryn M Heyob; Loren E Wold; Lynette K Rogers
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-12-06       Impact factor: 4.733

Review 7.  MicroRNAs: a new piece in the paediatric cardiovascular disease puzzle.

Authors:  Ahmed Omran; Dalia Elimam; Keith A Webster; Lina A Shehadeh; Fei Yin
Journal:  Cardiol Young       Date:  2013-02-26       Impact factor: 1.093

Review 8.  Emerging Roles for MicroRNAs in Perioperative Medicine.

Authors:  Viola Neudecker; Kelley S Brodsky; Simone Kreth; Adit A Ginde; Holger K Eltzschig
Journal:  Anesthesiology       Date:  2016-02       Impact factor: 7.892

Review 9.  MicroRNAs, heart failure, and aging: potential interactions with skeletal muscle.

Authors:  Kevin A Murach; John J McCarthy
Journal:  Heart Fail Rev       Date:  2017-03       Impact factor: 4.214

10.  The Role of MicroRNAs in Antiarrhythmic Therapy for Atrial Fibrillation.

Authors:  Sebastian Clauss; Moritz F Sinner; Stefan Kääb; Reza Wakili
Journal:  Arrhythm Electrophysiol Rev       Date:  2015-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.